Document is current

Article History

Received: 5 May 2025

Accepted: 12 August 2025

First Online: 2 October 2025

Competing interests

: Nour Abuhadra, abuhadn@mskcc.org: Professional Services and Activities for Boxer Capital, LLC, Medscape, MJH Life Sciences, and OncLive. Fresia Pareja, parejaf@mskcc.org: Membership on the Scientific Advisory Board of MultiplexDx; Consultancy Fees and Membership on the Advisory Board of AstraZeneca; Funding from National Institutes of Health grant No. NIH/NCI P50 CA24779 01 and from a grant from the Starr Cancer Consortium. Stephanie Downs-Canner, downscas@mskcc.org: Funding from National Institutes of Health grant No. NIH/NCI 1 K08 CA259533-01A1. Larry Norton, nortonl@mskcc.org: Founding Editor-in-Chief and Advisory Editor, npj Breast Cancer. Atif Khan, khana7@mskcc.org: Research grants from Merck, Clovis Oncology, and Varian; Patents: Patent awarded for oncology use for the drug riluzole; Stock/Stock Options: Novavax and Xtrava Inc. Sarat Chandarlapaty, chandars@mskcc.org: Editor-in-Chief, npj Breast Cancer; Professional Services and Activities for AstraZeneca, Blueprint Medicines, Casdin Capital, LLC, Daiichi Sankyo, Encore Medical Education. Genesis Therapeutics, Novartis, Prelude Therapeutics, SAGA Diagnostics, and Springer Nature Limited; Uncompensated Professional Services and Activities for Eli Lilly and Company; Equity in Totus Medicines Inc. Pedram Razavi, razavip@mskcc.org: Consultant/Ad Board/Advisor for: Novartis, AstraZeneca, Pfizer, Lilly, Tempus, Prelude Therapeutics, NeoGenomics, Regor Pharmaceuticals, Natera, SAGA Diagnostics, Guardant Health, Myriad, and Foresight Diagnostics; Grant/Research Support: Institutional/grant funding from Grail, Novartis, AstraZeneca, Biothernostics, Tempus, Sophia Genetics, Biovica, Guardant Health, Personalis, Myriad, Foresight Diagnostics, and SAGA Diagnostics. Mark Robson, robsonm@mskcc.org: Professional Services and Activities for Change Healthcare Inc., Clinical Care Options, Genome Quebec, myMedEd, Inc., and WebMD; Uncompensated Professional Services and Activities for Artios Pharma Limited, AstraZeneca, Foundation Medicine, and Pfizer, Inc.All other authors declare no financial or non-financial competing interests.